BackAgios Pharmaceuticals Overview
Agios Pharmaceuticals Inc

Agios Pharmaceuticals Target Price

Where could AGIO trade next? Consensus target price: $45.

Get informed when a big investor buys or sells

+ Follow

Share Price

$34.03

Average Target Price

$45.0032.2% upside

6 analysts in the last 4 months

High: $55 | Low: $32

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-30H.C. Wainwright$5561.6% upsideOpen
2026-07-21H.C. WainwrightEmily Bodnar$5252.8% upsideOpen
2026-07-07Truist Financial$4120.5% upsideOpen
2026-07-07RBC Capital$326% downsideOpen
2026-06-15H.C. WainwrightEmily Bodnar$5458.7% upsideOpen
2026-04-30Truist Financial$365.8% upsideOpen
2026-04-20H.C. WainwrightEmily Bodnar$5046.9% upsideOpen
2026-02-12Truist FinancialGreg Renza$3914.6% upsideOpen
2025-12-26Leerink Partners$4017.5% upsideOpen
2025-12-24H.C. Wainwright$6282.2% upsideOpen
2025-12-24Truist FinancialGregory Renza$3811.7% upsideOpen
2025-11-24Truist Financial$326% downsideOpen
2025-11-20Goldman Sachs$2526.5% downsideOpen
2025-11-20Leerink Partners$340.1% downsideOpen
2025-10-20H.C. WainwrightEmily Bodnar$5664.6% upsideOpen
2025-05-02ScotiabankGreg Harrison$71108.6% upsideOpen
2024-10-31Raymond JamesDanielle Brill$5149.9% upsideOpen
2024-09-27Leerink PartnersAndrew Berens$5664.6% upsideOpen
2024-09-10Raymond JamesChris Raymond$5664.6% upsideOpen
2024-06-17Raymond JamesChris Raymond$5561.6% upsideOpen
2024-06-03RBC CapitalGregory Renza$5355.7% upsideOpen
2024-05-28Raymond JamesChris Raymond$4532.2% upsideOpen
2023-02-03Piper Sandler$4120.5% upsideOpen
2022-12-01J.P. Morgan$333% downsideOpen
2022-11-17Goldman Sachs$326% downsideOpen
2021-04-30BarclaysPeter Lawson$70105.7% upsideOpen

Agios Pharmaceuticals (AGIO) FAQ

Agios Pharmaceuticals's target price stands at $45. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $45 for AGIO implies 32.2% upside versus today's price ($34.03). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Agios Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places AGIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Agios Pharmaceuticals's reading of $45 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.